Triaziquone
Jump to navigation
Jump to search
This article relies largely or entirely on a single source. (September 2014) |
![]() | |
| Gene therapy | |
|---|---|
| Clinical data | |
| Other names | 2,3,5-Tris(aziridin-1-yl)cyclohexa-2,5-diene-1,4-dione |
| ATC code | |
| Physiological data | |
| Legal status | |
| Pharmacokinetic data | |
| Identifiers | |
| |
| CAS Number | |
| PubChem Template:Abbreviation | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| Chemical and physical data | |
| Formula | C12H13N3O2 |
| Molar mass | 231.25 g/mol |
| 3D model (JSmol) | |
| |
| |
| Template:Xmark | |
Triaziquone is a drug used in chemotherapy.
It is an alkylating agent.[1] It can react with DNA to form intrastrand crosslinks.[citation needed]
References
- ↑ Begleiter A (2000). "Clinical applications of quinone-containing alkylating agents". Front. Biosci. 5: E153–71. PMID 11056078.
Categories:
- Articles needing additional references from September 2014
- Articles with invalid date parameter in template
- All articles needing additional references
- Articles with short description
- Articles with changed ChemSpider identifier
- Articles with changed EBI identifier
- Infobox-drug molecular-weight unexpected-character
- Articles with changed InChI identifier
- Pages using infobox drug with unknown parameters
- Chemical pages without DrugBank identifier
- Drugs with no legal status
- Drugboxes which contain changes to verified fields
- Drugboxes which contain changes to watched fields
- All articles with unsourced statements
- Articles with unsourced statements from November 2013
- Drug
